Editorial: Innovative Immunotherapy Strategies for Enhanced Treatment of Hodgkin and Non-Hodgkin Lymphomas

Michael John Robertson^1*Eric Vivier²Penny Fang³

• ¹Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, United States
• ²Centre d'Immunologie de Marseille-Luminy, Marseille, France
• ³Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Houston, United States

affect tumor cells indirectly by modifying the tumor microenvironment. The patient did not experience cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS).Luo et al. took a sequential approach to treat a patient with refractory Burkitt lymphoma. Highdose chemotherapy and autologous peripheral blood stem cell transplantation was done to reduce tumor bulk and as lymphodepletion, followed by infusion of CD19/CD22-directed CAR T-cells.Maintenance treatment with anti-PD-1 antibody tislelizumab was given after the patient achieved complete response. In addition to employing a dual targeting extracellular domain, the third generation CAR used in this study had a novel intracellular signaling domain that included a CD3 zeta motif and costimulatory elements of CD28 and TLR2.After apheresis has been done to collect autologous lymphocytes, bridging therapy is often needed to prevent rapid disease progression while awaiting production of CAR T-cells (5). Radiotherapy may offer advantages compared to chemotherapy for bridging therapy (5,6). Ruan et al. (10). Among 265 newly diagnosed patients with MZL reported by Wang et al., 66% had MALT lymphoma and the remaining cases were about equally distributed between nodal and splenic MZL. Overall response rates did not differ between patients receiving rituximab plus chemotherapy versus obinutuzumab plus chemotherapy. However, in a subgroup analysis of 51 patients with high tumor burden the overall response rate favored obinutuzumab over rituximab. This observation requires confirmation in prospective studies with larger numbers of patients that have high tumor burden.Primary large B cell lymphomas of immune-privileged sites include primary DLBCL of the central nervous system (PCNSL), primary vitreoretinal DLBCL (PVRL), and primary testicular DLBCL (PTL). These aggressive lymphomas were grouped together in the 5 th Edition of the World Health Organization Classification of Lymphoid Neoplasms based on their common biological features (11). L. Wang et al.(https://doi.org/10.3389/fimmu.2025.1533444) have reviewed the epidemiology, pathogenesis, prognosis, and therapy of PCNSL, PVRL, and PTL. They discuss several novel therapeutic approaches involving small molecule inhibitors, antibody-drug conjugates, bispecific antibodies, and CAR-T cells for treatment of these challenging diseases.